Non-invasive tests (NITs) to risk-stratify patients with noncirrhotic metabolic-associated steatohepatitis (MASH) in a specialty setting who are eligible for resmetirom: cost-effectiveness analysis from a US payer perspective

Poster Presentation 

File size: 245.31 KB
Created: 17-06-2025
Updated: 18-06-2025
Hits: 14
Download Preview

© Madrigal Pharmaceuticals, Inc. All rights reserved.
MED-AT-MGL-3196-2300027

Go to Top